Clinical trials: Methamphetamine
Methamphetamine Dependence
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
- Trial name
- NCT00730522
- Testing
- CPP-109 vigabatrin
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Depression, Dual Diagnosis
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
Methamphetamine (MA) addiction is a public health concern that causes substantial harm to individual users, and imposes an economic burden in the U.S. totaling up to $48.3 billion annually.
- Conditions
- Depression, Dual Diagnosis, Drug Addiction
- Trial name
- NCT02192931
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Perry Renshaw
Methamphetamine or Cocaine Dependence
Doxazosin for Psychostimulant Dependence
Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder.
- Trial name
- NCT01371851
- Testing
- Doxazosin extended release
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
HIV-1-infection, Methamphetamine-dependence
Effect of Methamphetamine on Residual Latent HIV Disease Study
The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation.
- Trial name
- EMRLHD (NCT03825536)
- Testing
- Oral Methamphetamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Methamphetamine Abuse, Methamphetamine Dependence
Safety Assessment of Atomoxetine With MA IV Administration
This is a study of 4 nontreatment seeking individuals who were MA-dependent and the safety and tolerability of atomoxetine. This double-blind, placebo-controlled, within-subjects study is to determine the safety and tolerability…
- Trial name
- NCT01019707
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Los Angeles
Substance Use Disorders, Methamphetamine Abuse
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Trial name
- NCT06316973
- Testing
- CS-1103, Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.
Methamphetamine Dependence
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Modafinil is a non-amphetamine type stimulant that acts as a wakefulness-promoting drug, and is approved for managing symptoms of narcolepsy (i.e., daytime somnolence).
- Trial name
- Modafinil (NCT00469508)
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Depression, Dual Diagnosis
Open-Label Creatine Study for Female Meth Users
Study Purposes and Objectives: The objectives should be stated in such a way that the reader can determine the appropriateness of the study design. If appropriate, state the specific hypotheses being tested and/or study aims.
- Conditions
- Depression, Dual Diagnosis, Substance Use
- Trial name
- NCT02189915
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Methamphetamine Dependence
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
The purpose of this study is to examine the ability of atomoxetine compared to placebo to increase time to relapse in methamphetamine dependent volunteers.
- Trial name
- ATM (NCT01557569)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas